Skip to main content

Geron Corporation (GERN)

NASDAQ: GERN · IEX Real-Time Price · USD
1.38
+0.01 (0.73%)
After-hours:Sep 24, 2021 6:30 PM EDT
1.37
-0.08 (-5.52%)
At close: Sep 24, 4:00 PM
Market Cap464.87M
Revenue (ttm)402,000
Net Income (ttm)-100.84M
Shares Out327.03M
EPS (ttm)-0.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,388,386
Open1.45
Previous Close1.45
Day's Range1.37 - 1.45
52-Week Range1.20 - 2.36
Beta1.12
AnalystsStrong Buy
Price Target4.20 (+206.6%)
Est. Earnings DateNov 4, 2021

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte...

IndustryBiotechnology
IPO DateJun 30, 1996
CEOJohn Scarlett
Employees53
Stock ExchangeNASDAQ
Ticker SymbolGERN
Full Company Profile

Financial Performance

In 2020, Geron's revenue was $253,000, a decrease of -45.00% compared to the previous year's $460,000. Losses were -$75.62 million, 10.3% more than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Geron stock is "Strong Buy." The 12-month stock price forecast is 4.20, which is an increase of 206.57% from the latest price.

Price Target
$4.20
(206.57% upside)
Analyst Consensus: Strong Buy

News

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 400,000 shares of Geron common stock as...

1 week ago - Business Wire

Geron Announces September Investor Conference Presentation Webcasts

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following...

3 weeks ago - Business Wire

Here's What Investors Need From Geron

It could be a while before Geron has a big catalyst.

4 weeks ago - The Motley Fool

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 550,000 shares of Geron common stock as ...

1 month ago - Business Wire

Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of 0.00% and 33.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: Geron Q2 Earnings

Shares of Geron (NASDAQ:GERN) rose 2.5% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 50.00% over the past year to ($0.09), which missed t...

1 month ago - Benzinga

Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported updates on the IMerge Phase 3 trial in lower risk MDS and financia...

1 month ago - Business Wire

Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021

1 month ago - Business Wire

Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,000 shares of Geron common stock as ...

2 months ago - Business Wire

Geron (GERN) Soars on Imetelstat Data for Myelofibrosis

Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.

3 months ago - Zacks Investment Research

Do Options Traders Know Something About Geron (GERN) Stock We Don't?

Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Why Geron Stock Is Soaring Today

Investors are cheering the company's encouraging phase 2 data.

3 months ago - The Motley Fool

Geron Stock Trading Is Higher On Reinforcing Imetelstat's Approach For Myelofibrosis Treatment, With Data Publication...

Geron Corporation (NASDAQ: GERN) stock is trading higher during the premarket in reaction to data publication from the IMbark Phase 2 trial of imetelstat for myelofibrosis (MF) in the Journal of Clinica...

3 months ago - Benzinga

Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in...

3 months ago - Business Wire

Geron Reports Two Presentations at Virtual European Hematology Association Annual Congress

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses r...

3 months ago - Business Wire

Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses r...

4 months ago - Business Wire

Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of -12.50% and 82.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Geron: Q1 Earnings Insights

Shares of Geron (NASDAQ:GERN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 12.50% over the past year to ($0.09), which missed the estimat...

4 months ago - Benzinga

Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic...

4 months ago - Business Wire

Geron to Announce First Quarter 2021 Financial Results on May 10, 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2021 financial results after the market closes on Monday, May 10, 2021 via p...

4 months ago - Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 220,000 shares of Geron common stock as ...

5 months ago - Business Wire

SHAREHOLDER ALERT: Geron Corporation (GERN) Officers and Directors Under Investigation for False Statements and Insid...

SAN FRANCISCO, April 19, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Geron Corporation (NASDAQ: GERN) relating to possib...

5 months ago - PRNewsWire

Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat

Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.

5 months ago - Zacks Investment Research

Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-cla...

5 months ago - Business Wire